Literature DB >> 17687385

Maximizing mouse cancer models.

Kristopher K Frese1, David A Tuveson.   

Abstract

Animal models of cancer provide an alternative means to determine the causes of and treatments for malignancy, thus representing a resource of immense potential for cancer medicine. The sophistication of modelling cancer in mice has increased to the extent that investigators can both observe and manipulate a complex disease process in a manner impossible to perform in patients. However, owing to limitations in model design and technology development, and the surprising underuse of existing models, only now are we realising the full potential of mouse models of cancer and what new approaches are needed to derive the maximum value for cancer patients from this investment.

Entities:  

Mesh：

Year:  2007        PMID： 17687385     DOI： 10.1038/nrc2192

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  302 in total

1.  Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.

Authors:  Gregory P Botta; Mauricio J Reginato; Maximilian Reichert; Anil K Rustgi; Peter I Lelkes
Journal:  Mol Cancer Res       Date:  2011-12-08       Impact factor: 5.852

Review 2.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.

Authors:  Vathany Kulasingam; Maria P Pavlou; Eleftherios P Diamandis
Journal:  Nat Rev Cancer       Date:  2010-04-12       Impact factor: 60.716

3.  Raising the bar for cancer therapy models.

Authors:  Giulio Francia; Robert S Kerbel
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

Review 4.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 5.  Modeling metastasis in the mouse.

Authors:  Paula D Bos; Don X Nguyen; Joan Massagué
Journal:  Curr Opin Pharmacol       Date:  2010-07-01       Impact factor: 5.547

6.  Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.

Authors:  Zhao Chen; Esra Akbay; Oliver Mikse; Tanya Tupper; Katherine Cheng; Yuchuan Wang; Xiaohong Tan; Abigail Altabef; Sue-Ann Woo; Liang Chen; Jacob B Reibel; Pasi A Janne; Norman E Sharpless; Jeffrey A Engelman; Geoffrey I Shapiro; Andrew L Kung; Kwok-Kin Wong
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

7.  Contrast agents for quantitative microCT of lung tumors in mice.

Authors:  Kush Lalwani; Anand Giddabasappa; Danan Li; Peter Olson; Brett Simmons; Farbod Shojaei; Todd Van Arsdale; James Christensen; Amy Jackson-Fisher; Anthony Wong; Patrick B Lappin; Jeetendra Eswaraka
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

8.  Pathology Principles and Practices for Analysis of Animal Models.

Authors:  Sue E Knoblaugh; Tobias M Hohl; Krista M D La Perle
Journal:  ILAR J       Date:  2018-12-01

9.  Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.

Authors:  Panomwat Amornphimoltham; Kantima Leelahavanichkul; Alfredo Molinolo; Vyomesh Patel; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

10.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.